BioCentury
ARTICLE | Company News

China approves Roche’s Alecensa for NSCLC

August 20, 2018 4:53 PM UTC

Roche (SIX:ROG; OTCQX:RHHBY) said China’s State Drug Administration approved Alecensa alectinib as monotherapy to treat anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer. FDA and EMA approved the drug for the indication in November and December, respectively. The company said it will launch Alecensa later this year, but declined to comment on pricing.

Alecensa is one of 48 internationally-approved drugs identified this month by China’s Drug Evaluation Center as eligible for Priority Review (see “China Releases List of Overseas Drugs Eligible for Priority Review”)...

BCIQ Company Profiles

Roche